Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study
30 oct. 2024 08h30 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
Novo Nordisk A/S – Share repurchase programme
07 oct. 2024 06h44 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 7 October 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council...
Novo Nordisk A/S – Share repurchase programme
30 sept. 2024 07h02 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 30 September 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and...
Novo Nordisk A/S - share repurchase programme
09 sept. 2024 09h55 HE
|
Novo Nordisk A/S
Novo Nordisk A/S – Share repurchase programme Bagsværd, Denmark, 9 September 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No...
Novo Nordisk A/S – Share repurchase programme
12 août 2024 08h31 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 12 August 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council...
Novo Nordisk A/S – Share repurchase programme
29 juil. 2024 07h05 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 29 July 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16...
Novo Nordisk announces 4.1 billion USD investment to expand US manufacturing capacity
24 juin 2024 14h16 HE
|
Novo Nordisk A/S
In 2024, Novo Nordisk plans to boost its current investments, aiming to allocate USD 6.8 billion towards production, a significant increase from the previous year's investment of USD 3.9 billion*. ...
Biosplice Announces Collaboration with Novo Nordisk in Diabetes
13 juin 2024 06h00 HE
|
Biosplice Therapeutics, Inc.
Biosplice enters into a pre-clinical collaboration with Novo Nordisk to develop inhibitors of DYRK for diabetes
US Neurologists Report Route of Administration as a Critical Factor when Evaluating Future Parkinson’s Disease Treatments
09 mai 2024 09h31 HE
|
Spherix Global Insights
Exton, Pennsylvania, May 09, 2024 (GLOBE NEWSWIRE) -- Even as the incidence of Parkinson’s disease (PD) continues to increase with 90,000 new diagnoses each year1 in the US, the treatment landscape...
Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
02 avr. 2024 07h26 HE
|
Arch Biopartners
TORONTO, April 02, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that three additional clinical sites in Turkey have...